1	Genetics	NNP	2	nn
2	Institute	NNP	3	nn
3	Inc.	NNP	9	nsubj
4	,	,	3	punct
5	Cambridge	NNP	7	nn
6	,	,	7	punct
7	Mass.	NNP	3	appos
8	,	,	3	punct
9	said	VBD	0	root
10	it	PRP	12	nsubjpass
11	was	VBD	12	auxpass
12	awarded	VBN	9	ccomp
13	U.S.	NNP	14	nn
14	patents	NNS	12	dobj
15	for	IN	12	prep
16	Interleukin-3	NN	15	pobj
17	and	CC	16	cc
18	bone	NN	20	nn
19	morphogenetic	JJ	20	amod
20	protein	NN	16	conj
21	.	.	9	punct

1	The	DT	2	det
2	patent	NN	5	nsubj
3	for	IN	2	prep
4	Interleukin-3	NN	3	pobj
5	covers	VBZ	0	root
6	materials	NNS	5	dobj
7	and	CC	6	cc
8	methods	NNS	6	conj
9	used	VBN	6	partmod
10	to	TO	11	aux
11	make	VB	9	xcomp
12	the	DT	17	det
13	human	JJ	15	amod
14	blood	NN	15	nn
15	cell	NN	17	nn
16	growth	NN	17	nn
17	factor	NN	11	dobj
18	via	IN	11	prep
19	recombinant	JJ	20	amod
20	DNA	NNP	21	nn
21	technology	NN	18	pobj
22	.	.	5	punct

1	Sandoz	NNP	2	nn
2	Ltd.	NNP	4	nsubj
3	has	VBZ	4	aux
4	licensed	VBN	0	root
5	certain	JJ	9	amod
6	manufacturing	NN	9	nn
7	and	CC	6	cc
8	marketing	NN	6	conj
9	rights	NNS	4	dobj
10	for	IN	9	prep
11	Interleukin-3	NN	10	pobj
12	from	IN	4	prep
13	Genetics	NNP	14	nn
14	Institute	NNP	12	pobj
15	and	CC	4	cc
16	is	VBZ	17	aux
17	conducting	VBG	4	conj
18	preclinical	JJ	19	amod
19	studies	NNS	17	dobj
20	with	IN	17	prep
21	it	PRP	20	pobj
22	.	.	4	punct

1	Interleukin-3	NN	3	nsubj
2	may	MD	3	aux
3	help	VB	24	ccomp
4	in	IN	3	prep
5	treating	VBG	4	pcomp
6	blood	NN	7	nn
7	cell	NN	8	nn
8	deficiencies	NNS	5	dobj
9	associated	VBN	8	partmod
10	with	IN	9	prep
11	cancer	NN	12	nn
12	treatment	NN	10	pobj
13	,	,	12	punct
14	bone	NN	15	nn
15	marrow	NN	16	nn
16	transplants	NNS	12	conj
17	and	CC	12	cc
18	other	JJ	20	amod
19	blood-cell	NN	20	nn
20	disorders	NNS	12	conj
21	,	,	24	punct
22	Genetics	NNP	23	nn
23	Institute	NNP	24	nsubj
24	said	VBD	0	root
25	.	.	24	punct

1	The	DT	3	det
2	second	JJ	3	amod
3	patent	NN	4	nsubj
4	describes	VBZ	0	root
5	bone	NN	7	nn
6	morphogenetic	JJ	7	amod
7	protein-1	NN	4	dobj
8	,	,	7	punct
9	a	DT	10	det
10	substance	NN	7	appos
11	that	WDT	13	nsubj
12	can	MD	13	aux
13	induce	VB	10	rcmod
14	formation	NN	13	dobj
15	of	IN	14	prep
16	new	JJ	17	amod
17	cartilage	NN	15	pobj
18	.	.	4	punct

1	The	DT	2	det
2	patent	NN	3	nsubj
3	covers	VBZ	21	ccomp
4	BMP-1	NN	5	nn
5	type	NN	6	nn
6	proteins	NNS	3	dobj
7	and	CC	6	cc
8	pharmaceutical	JJ	9	amod
9	compositions	NNS	6	conj
10	and	CC	9	cc
11	methods	NNS	9	conj
12	for	IN	9	prep
13	treating	VBG	12	pcomp
14	bone	NN	17	nn
15	or	CC	14	cc
16	cartilage	NN	14	conj
17	defects	NNS	13	dobj
18	,	,	21	punct
19	Genetics	NNP	20	nn
20	Institute	NNP	21	nsubj
21	said	VBD	0	root
22	.	.	21	punct

1	The	DT	2	det
2	company	NN	3	nsubj
3	added	VBD	0	root
4	that	IN	7	complm
5	it	PRP	7	nsubj
6	has	VBZ	7	aux
7	filed	VBN	3	ccomp
8	patent	NN	9	nn
9	applications	NNS	7	dobj
10	``	``	7	punct
11	on	IN	7	prep
12	a	DT	14	det
13	large	JJ	14	amod
14	number	NN	11	pobj
15	of	IN	14	prep
16	different	JJ	18	amod
17	BMP	NN	18	nn
18	proteins	NNS	15	pobj
19	''	''	7	punct
20	and	CC	3	cc
21	the	DT	22	det
22	patent	NN	27	nsubj
23	on	IN	22	prep
24	BMP-1	NN	23	pobj
25	is	VBZ	27	cop
26	the	DT	27	det
27	first	JJ	3	conj
28	it	PRP	30	nsubj
29	has	VBZ	30	aux
30	received	VBN	27	rcmod
31	.	.	3	punct

1	BMP	NN	2	nn
2	products	NNS	5	nsubj
3	may	MD	5	aux
4	be	VB	5	cop
5	useful	JJ	24	ccomp
6	in	IN	5	prep
7	fracture	NN	8	nn
8	healing	NN	6	pobj
9	and	CC	6	cc
10	in	IN	6	conj
11	treating	VBG	10	pcomp
12	bone	NN	13	nn
13	loss	NN	11	dobj
14	associated	VBN	13	partmod
15	with	IN	14	prep
16	periodontal	JJ	17	amod
17	disease	NN	15	pobj
18	and	CC	17	cc
19	certain	JJ	20	amod
20	cancers	NNS	17	conj
21	,	,	24	punct
22	the	DT	23	det
23	company	NN	24	nsubj
24	said	VBD	0	root
25	.	.	24	punct


